简短通讯：奈韦拉平血浆水平、慢性丙型肝炎与HIV感染患者肝毒性发生之间的相互作用

Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.

作者信息

Núñez Marina, González-Requena Daniel, González-Lahoz Juan, Soriano Vincent

机构信息

Department of Infectious Diseases, Instituto de Salud Carlos III, 28035 Madrid, Spain.

出版信息

AIDS Res Hum Retroviruses. 2003 Mar;19(3):187-8. doi: 10.1089/088922203763315687.

DOI:10.1089/088922203763315687

PMID:12689410

Abstract

Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy. NVP is metabolized in the liver and its clearance could be altered in the presence of chronic hepatitis C virus (HCV) infection, enhancing the risk of liver toxicity. We examined NVP plasma levels in 70 HIV-infected subjects receiving NVP-containing triple combinations. The median (range) NVP plasma trough concentrations were similar in 32 HCV antibody-positive and 38 HCV antibody-negative patients (5.8 [0.7-29] vs. 6.1 [0.9-9.6] microg/ml). Thus, HCV coinfection itself does not seem to influence significantly the pharmacokinetics of NVP in HIV-infected subjects.

摘要

慢性丙型肝炎和使用奈韦拉平（NVP）均为高效抗逆转录病毒治疗下转氨酶升高的危险因素。NVP在肝脏中代谢，在慢性丙型肝炎病毒（HCV）感染的情况下其清除率可能改变，从而增加肝毒性风险。我们检测了70例接受含NVP三联疗法的HIV感染受试者的NVP血浆水平。32例HCV抗体阳性和38例HCV抗体阴性患者的NVP血浆谷浓度中位数（范围）相似（5.8 [0.7 - 29] 对 6.1 [0.9 - 9.6] μg/ml）。因此，合并HCV感染本身似乎对HIV感染受试者中NVP的药代动力学没有显著影响。